ZURICH, March 2 (Reuters) - Actelion Ltd needs to do further risk analysis on key drug Tracleer before U.S. regulators decide whether its use can be extended to patients with a less severe form of a rare heart and lung disease.
ZURICH, March 2 (Reuters) - Actelion Ltd needs to do further risk analysis on key drug Tracleer before U.S. regulators decide whether its use can be extended to patients with a less severe form of a rare heart and lung disease.
